Multimodal Deep Learning for Predicting Treatment Response to Neoadjuvant Chemoimmunotherapy in Esophageal Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-06-01

Study Completion Date

2026-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This observational study aims to investigate a clinical cohort of patients with locally advanced esophageal cancer undergoing neoadjuvant chemoimmunotherapy. By integrating multimodal clinical data-including demographic characteristics, medical history, imaging studies, pathological findings, and laboratory tests-and employing deep learning algorithms, the study seeks to develop predictive models for the early and accurate assessment of treatment response prior to surgery. Specifically, this study focuses on addressing the following key scientific questions:

1. Can multimodal clinical data be used to construct an accurate model for predicting pathological complete response (pCR) following neoadjuvant therapy?
2. Can deep learning models enable early identification of patients with suboptimal response to neoadjuvant therapy, defined as stable disease (SD) or progressive disease (PD), before surgery?

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy

NCT07088354

Esophageal Squamous Cell Carcinoma Neoadjuvant Immunochemotherapy Pathological Complete Response +1 more

RECRUITING

Development and Application of AI-Based Therapeutic Strategies for Esophageal Cancer Integrating Multimodal Imaging and Digital Pathology

NCT07203690

Esophageal Cancer Neoadjuvant Therapy

NOT_YET_RECRUITING

Response Prediction to Neoadjuvant Chemoradiation in Esophageal Cancer Using Artificial Intelligence & Machine Learning

NCT04489368

Esophageal Neoplasm

UNKNOWN

Multimodal Endoscopic Image Fusion for Assessing Infiltration in Superficial Esophageal Squamous Cell Carcinoma

NCT06412419

Esophageal Neoplasms Malignant

NOT_YET_RECRUITING

Changhai Multimodal Esophageal Cancer Cohort

NCT06410677

Esophageal Squamous Cell Carcinoma

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Esophagus Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

group 1: pCR

group 1: Pathologic Complete Response

No interventions assigned to this group

group 2: Non-pCR

group 2: Non-Pathological Complete Response

No interventions assigned to this group

group 3: Non-Favorable Responses

group 3: SD/PD

No interventions assigned to this group

group 4: Favorable Response

group 4: Non-SD/PD

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with histologically confirmed esophageal cancer based on biopsy results;
2. Patients recommended for neoadjuvant chemoimmunotherapy following multidisciplinary team (MDT) discussion or evaluation by thoracic surgery specialists;
3. Patients who received neoadjuvant chemoimmunotherapy;
4. Patients with complete imaging data before and after neoadjuvant treatment.

Exclusion Criteria

1. Patients deemed eligible for surgery by the thoracic surgery team but who refused surgical treatment;
2. Patients with missing or poor-quality CT images;
3. Patients with concurrent malignancies other than esophageal cancer;
4. Patients with incomplete clinical data.

Eligible Sex

ALL

Accepts Healthy Volunteers

No